DermTech, Inc. - DMTK STOCK NEWS

DermTech (NASDAQ: DMTK) announced stock options for one new employee to purchase 135,397 shares at $6.35 each and grants of restricted stock units for 28 employees representing up to 569,240 shares. These grants are part of the 2022 Inducement Equity Incentive Plan and were effective June 5, 2022. The stock options will vest over four years while the restricted stock units will vest in quarterly installments until June 5, 2026. This strategic move aims to attract and retain talent in the company's pursuit of precision dermatology.

DermTech, Inc. (NASDAQ: DMTK) announces management's presentation at the William Blair Growth Stock Conference on June 8, 2022, at 2:00 p.m. CT. The presentation will be accessible via a live webcast on DermTech's investor relations page, with a replay available for 90 days. DermTech specializes in precision dermatology, focusing on non-invasive skin genomics to enhance individualized care and early skin cancer detection. Their innovative products utilize Smart Stickers for genomic analysis of skin samples.

DermTech (NASDAQ: DMTK) has announced its sponsorship of The Sun Bus, a mobile initiative providing free skin cancer screenings and education across the U.S. The program, organized in partnership with the Colorado Melanoma Foundation and Epiphany Dermatology, aims to reach over 50 locations in 2022. Launching in April 2022, it will travel through multiple states offering free skin checks and sun safety education. DermTech’s Melanoma Test offers a non-invasive method to detect melanoma early, boasting high accuracy with a negative result indicating a greater than 99% chance of no melanoma.

DermTech (NASDAQ: DMTK) presented innovative research at the Society for Investigative Dermatology’s annual meeting from May 18-21, 2022, in Portland, OR. The study, led by Dr. Michael Howell, evaluates a non-invasive method using the Smart Sticker™ to differentiate between atopic dermatitis and psoriasis. This technology leverages genomic analysis of skin samples, identifying significant biomarkers such as IL-13 and IL-17A. The findings aim to enhance clinical decision-making and treatment options for these prevalent skin conditions affecting up to 10% and 3% of the U.S. population, respectively.

DermTech (NASDAQ: DMTK) has expressed support for the Biden Administration's renewed Cancer Moonshot program, aimed at improving cancer detection and treatment. This initiative aligns with DermTech's mission to enhance early detection of melanoma through its non-invasive DermTech Melanoma Test, which significantly boosts survival rates. The company emphasizes the importance of accessibility in dermatologic care, especially for underserved communities. DermTech is committed to making melanoma detection straightforward, leveraging its Smart Sticker technology to improve patient outcomes.

DermTech (NASDAQ: DMTK) announced the return of its #Stickit2Melanoma campaign, aimed at raising awareness of melanoma during Skin Cancer Awareness Month. Kicking off on May 2, 2022, the initiative encourages skin exams with a $5 donation to skin health nonprofits for each pledge. DermTech plans to donate up to $1 million over four years, building on last year's $250,000. The campaign emphasizes early detection, crucial for improving survival rates, especially as the five-year survival rate drops from 99.4% to 29.8% if melanoma spreads.

DermTech, Inc. (NASDAQ: DMTK) reported first-quarter 2022 financial results, highlighting a record growth in billable sample volume, which increased by 53% to approximately 14,370. Assay revenue surged 61% year-over-year to $3.5 million, contributing to total revenue of $3.7 million, a 47% rise. However, net loss was $30.1 million ($1.01 per share), up from $15.1 million in Q1 2021. The company affirmed its 2022 assay revenue outlook of $22-$26 million and expanded telehealth services, now covering 95% of the U.S. population.

DermTech has announced the publication of a significant study focusing on chronic cutaneous graft-versus-host disease (cGvHD), evaluating the efficacy of topical ruxolitinib cream. This is the first clinical trial analyzing gene expression changes in cGvHD patients treated with this cream versus a vehicle. The study, conducted with the Memorial Sloan Kettering Cancer Center, identified 210 differentially expressed genes linked to immune modulation and treatment response. This research enhances DermTech's position in precision dermatology and aims to provide actionable genomic insights for clinicians.

DermTech (NASDAQ: DMTK) has expanded its telehealth application, DermTech Connect, from 8 states to 44, reaching around 95% of the U.S. population. This app allows patients to submit photos of moles for dermatologist evaluation at a low cost, with results typically available within 48 hours. Additionally, the proprietary DermTech Melanoma Test can be ordered if necessary, enhancing early detection of melanoma, a serious skin cancer. The app is available for download on both Apple and Android platforms.